Potential role of rivaroxaban in patients with acute coronary syndrome

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 349-357

  Fitchett, David H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Anticoagulation; Bleeding risk; Cardiovascular death; Myocardial infarction; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; PLACEBO; PRASUGREL; PROTHROMBIN A; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEATH; DOSE RESPONSE; DRUG EXCRETION; DRUG FATALITY; DRUG MEGADOSE; EARLY INTERVENTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MORTALITY; NONHUMAN; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; THROMBOSIS;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MORPHOLINES; RISK; THIOPHENES; THROMBOEMBOLISM; THROMBOSIS; WARFARIN;

EID: 84872353277     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S30342     Document Type: Review

References (37)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
3. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61-68.
4. Cohen M, Demers C, Gurfnkel E, et al. A comparison of low-molecularweight heparin with unfractionated heparin for unstable coronary artery disease. Effcacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447-452.
5. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-1476.
6. Stone G W, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355(21):2203-2216.
7. Husted SE, Wallentin L, Lagerqvist B, Kontny F, Ståhle E, Swahn E. Benefts of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J. 2002;23(15):1213-1218.
8. Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J. 2000;34(2):168-171.
9. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol. 2001;37(2):475-484.
10. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241-250.
11. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fbrillation. Arch Intern Med. 2010;170(16): 1433-1441.
12. Wright SA, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920-1959.
13. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fbrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691-1698.
14. Pradax product monograph. Boehringer Ingelheim Canada. January 27, 2012.
15. Patel MR, Mahaffey K W, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365:883-891.
16. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009;37(5): 1056-1064.
17. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9-19.
18. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362(9386):789-797.
19. Oldgren J, Budaj A, Granger CB, et al; RE-DEEM Investigators. Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781-2789.
20. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877-2885.
21. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.
22. Steg PG, Mehta SR, Jukema J W, et al; RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32(20): 2541-2554.
23. Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, doubleblind, phase II trial. Lancet. 2009;374(9683):29-38.
24. Janssen Research and Development. Rivaroxaban for Reducing the Risk of Cardiovascular Events (Cardiovascular Death, Myocardial Infarction and Stroke) After Acute Coronary Syndrome (ACS). Advisory committee briefng document JNJ-39039039; BAY 59-7939 (rivaroxaban). Raritan, NJ: Janssen Research and Development; April 24, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM304757. pdf. Accessed June 14, 2012.
25. Davis MJ, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310(18):1138-1140.
26. US Food and Drug Administration (FDA). FDA Briefng Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). NDA: 202439/S-002. Drug: Xarelto® (Rivaroxaban) oral tablets. Silver Spring, MD: FDA; May 23, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM304755.pdf. Accessed June 14, 2012.
27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
28. van Es R F, Jonker JJ, Verheugt F W, Deckers J W, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet. 2002;360:109-113.
29. Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fbrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation. 2002;106:659-665.
30. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347: 969-974.
31. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol. 2001;37:475-484.
32. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation. 1998;98:1064-1070.
33. Huynh T, Théroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation. 2001;103:3069-3074.
34. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 1990;66:1287-1292.
35. Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol. 1997;30:364-369.
36. Zibaeenezhad MJ, Mowla A, Sorbi MH. Warfarin and aspirin versus aspirin alone in patients with acute myocardial infarction: a pilot study. Angiology. 2004;55:17-20.
37. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation. 1994;89(1):81-88.